WarfarinPharmacogeneticsAnticoagulantsVitamin K Epoxide ReductasesMixed Function OxygenasesAryl Hydrocarbon HydroxylasesProthrombin TimePhenindioneAcenocoumarolThromboembolismInternational Normalized RatioHemorrhagePhenprocoumonThrombophlebitisVitamin KPulmonary EmbolismAtrial FibrillationVenous ThrombosisHeparin, Low-Molecular-WeightIndividualized MedicineBlood CoagulationDicumarolbeta-AlanineHeparinAdministration, OralThrombosisVenous ThromboembolismInternational CooperationCytochrome P-450 CYP2D6Blood Coagulation TestsPolymorphism, GeneticRodenticidesAspirinGenotypeTreatment OutcomeHematomaDrug MonitoringAntithrombinsPlatelet Aggregation InhibitorsPartial Thromboplastin TimeLupus Coagulation InhibitorProthrombinBiomarkers, PharmacologicalDrug TherapyStrokeBlood Coagulation FactorsMicrobial Consortia4-HydroxycoumarinsDrug InteractionsThrombophiliaFibrinolytic AgentsRecurrenceEmbolismPolymorphism, Single NucleotideRisk FactorsBlood Coagulation DisordersCoumarinsFibrin Fibrinogen Degradation ProductsDrug-Related Side Effects and Adverse ReactionsHeart Valve ProsthesisEnoxaparinDose-Response Relationship, DrugProtein CDrug Dosage CalculationsBenzimidazolesInternational AgenciesPharmaceutical PreparationsFollow-Up StudiesGenetic VariationAntiphospholipid SyndromeTime FactorsClinical Trials as TopicHematoma, SubduralThiophenesProspective StudiesGenetic TestingCerebral HemorrhageRetrospective StudiesCytochrome P-450 Enzyme SystemMetabolic Detoxication, DrugIntracranial Embolism and ThrombosisRisk AssessmentTiclopidineFactor VIIPharmacy ResidenciesFactor XRandomized Controlled Trials as TopicThrombin TimeFactor XaOral Surgical ProceduresPipecolic AcidsCerebrovascular DisordersHemostasisThrombinVitamin K 1PhlebographyDihydrouracil Dehydrogenase (NADP)Antithrombin IIIDrug Administration ScheduleBenzylamines